81 related articles for article (PubMed ID: 11261500)
1. L-DOPA.
Hornykiewicz O
J Parkinsons Dis; 2017; 7(s1):S3-S10. PubMed ID: 28282813
[No Abstract] [Full Text] [Related]
2. Continuous levodopa production by an artificial enzyme.
Wood H
Nat Rev Neurol; 2023 Jul; 19(7):387. PubMed ID: 37225840
[No Abstract] [Full Text] [Related]
3. Device-aided therapies for Parkinson's disease: "All for one, one for all, that is our device".
Hall D
Parkinsonism Relat Disord; 2023 Nov; 116():105862. PubMed ID: 37778884
[No Abstract] [Full Text] [Related]
4. Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples.
Ugarte A; Corbacho D; Aymerich MS; García-Osta A; Cuadrado-Tejedor M; Oyarzabal J
Neurotherapeutics; 2018 Jul; 15(3):742-750. PubMed ID: 29675823
[TBL] [Abstract][Full Text] [Related]
5. Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa.
Cilia R; Cereda E; Akpalu A; Sarfo FS; Cham M; Laryea R; Obese V; Oppon K; Del Sorbo F; Bonvegna S; Zecchinelli AL; Pezzoli G
Brain; 2020 Aug; 143(8):2490-2501. PubMed ID: 32844196
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and Treatment of Parkinson Disease: A Review.
Armstrong MJ; Okun MS
JAMA; 2020 Feb; 323(6):548-560. PubMed ID: 32044947
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of Parkinson's disease.
Tysnes OB; Storstein A
J Neural Transm (Vienna); 2017 Aug; 124(8):901-905. PubMed ID: 28150045
[TBL] [Abstract][Full Text] [Related]
8. Parkinson's disease: a review.
Beitz JM
Front Biosci (Schol Ed); 2014 Jan; 6(1):65-74. PubMed ID: 24389262
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
10. The history of dopamine and levodopa in the treatment of Parkinson's disease.
Fahn S
Mov Disord; 2008; 23 Suppl 3():S497-508. PubMed ID: 18781671
[TBL] [Abstract][Full Text] [Related]
11. Levodopa and the progression of Parkinson's disease.
Walton-Hadlock JL
N Engl J Med; 2005 Mar; 352(13):1386; author reply 1386. PubMed ID: 15800240
[No Abstract] [Full Text] [Related]
12. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics.
LeWitt PA
Mov Disord; 2015 Jan; 30(1):64-72. PubMed ID: 25449210
[TBL] [Abstract][Full Text] [Related]
13. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease.
Deleu D; Jacob P; Chand P; Sarre S; Colwell A
Neurology; 2006 Sep; 67(5):897-9. PubMed ID: 16966563
[TBL] [Abstract][Full Text] [Related]
14. Inter- and intra-individual variation in L-dopa pharmacokinetics in the treatment of Parkinson's disease.
Nomoto M; Nishikawa N; Nagai M; Yabe H; Nakatsuka A; Moritoyo H; Moritoyo T; Kubo M
Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S21-4. PubMed ID: 19131037
[TBL] [Abstract][Full Text] [Related]
15. The neurochemistry of therapeutics: levodopa pharmacodynamics in Parkinson's disease.
Frey KA
Ann Neurol; 2001 Mar; 49(3):285-7. PubMed ID: 11261500
[No Abstract] [Full Text] [Related]
16. Levodopa for Parkinson's disease.
Gérard JM; Elosegi JA
N Engl J Med; 2009 Feb; 360(9):936; author reply 936. PubMed ID: 19256032
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
